📰 Thomas Biegi News
Page 3 - Thomas Biegi News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Thomas Biegi. Real-time updates on events, politics, business and more.
August 3, 2023
EQS-News: MorphoSys AG / Key word(s): Half Year ResultsInvitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023 03.08.2023 / 22:03 CET/CESTThe issuer is solely responsible for the content of this announcement.Conference Call AlertPlanegg/Munich, Germany, Augus...
June 14, 2023
EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023 14.06.2023 / 08:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, June 14, 2023 MorphoS...
June 14, 2023
EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023 14.06.2023 / 08:39... | June 14, 2023
May 18, 2023
EQS-News: MorphoSys AG / Key word(s): AGM/EGMMorphoSys AG Reports Outcome of Annual General Meeting 2023 17.05.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 17, 2023 MorphoSys AG Reports Outcome of Annual General Meeting 2023...
May 17, 2023
EQS-News: MorphoSys AG / Key word: AGM/EGM MorphoSys AG Reports Outcome of Annual General Meeting 2023 17.05.2023 / 22:01 CET/CEST The issuer is solely responsible for the... | May 17, 2023
May 11, 2023
EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39... | May 11, 2023
May 11, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 11, 2023 M...
May 3, 2023
Monjuvi U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline
May 3, 2023
EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement MorphoSys AG Reports First Quarter 2023 Financial Results ...
May 3, 2023
03.05.2023 - EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement MorphoSys AG Reports First Quarter 2023 Financial Results 03.05.2023 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release ...